

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Reference is made to the announcement of the Company dated March 28, 2025, in relation to, among others, the retirement of Ms. Liang Qian (“**Ms. Liang**”) as a non-executive director of the Company due to the expiration of her term of office, which will be effective from the approval of the Company’s shareholders (the “**Shareholders**”) to form a new board of directors (the “**Board**”) at an general meeting.

Following the retirement of Ms. Liang, the Board will comprise 11 directors of the Company (the “**Director(s)**”). Therefore, to reflect the changes in the number of Board members, the Board has proposed at the Board meeting to seek the approval of the Shareholders on the following amendments (the “**Proposed Amendments**”) to the articles of association of the Company:

Before the Amendment	After the Amendment
Article 109 The Board is composed of 12 Directors, including one chairman. At all times, at least one-third of the members of the Board shall be independent non-executive Directors, and the total number of independent non-executive Directors shall be not less than three, at least one of whom shall have appropriate professional qualifications in line with regulatory requirements, or appropriate accounting or related financial management expertise.	Article 109 The Board is composed of <u>12</u> 1 Directors, including one chairman. At all times, at least one-third of the members of the Board shall be independent non-executive Directors, and the total number of independent non-executive Directors shall be not less than three, at least one of whom shall have appropriate professional qualifications in line with regulatory requirements, or appropriate accounting or related financial management expertise.

The Proposed Amendments are prepared in Chinese language. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

The Proposed Amendments are subject to the Shareholders' approval by way of special resolution at a general meeting of the Company. A circular containing details of the aforementioned matter together with a notice convening the general meeting of the Company will be despatched to the Shareholders (if requested) and published on the Company's website (www.yzybio.com) and the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) as soon as possible.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Wuhan, PRC, May 27, 2025

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Mr. Wen Zhicheng and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.